40 results on '"Schub, Natalie"'
Search Results
2. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
3. Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease
4. Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
5. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT
6. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
7. Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie: Übersicht und Management früher und verzögerter Nebenwirkungen
8. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
9. Erratum zu: Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie
10. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
11. P-277: Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma
12. Allogeneic Stem Cell Transplantation with BEAM and Alemtuzumab Conditioning Immediately after Remission Induction Has Curative Potential in Advanced T-Cell Non-Hodgkin's Lymphoma
13. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer:a study of the Chronic Malignancies Working Party of the EBMT
14. Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network
15. Toxicity after chimeric antigen receptor T-cell therapy Overview and management of early and late onset side effects
16. Toxicity after chimeric antigen receptor T-cell therapy (Jun, 10.1007/s00108-021-01046-5, 2021)
17. The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis
18. Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT
19. Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT
20. Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease
21. Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network
22. Treatment of Severe Acute GvHD with Alemtuzumab Is Effective without Increased Relapse Rates
23. Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma
24. Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial
25. Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.
26. A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma
27. Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study
28. Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy
29. Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria
30. CD96 Antibody TH-111 Eradicates AML-LSC from Autografts and the Fc- Engineered Variant MSH-TH111e May be Used In Vivo
31. M.D
32. CD96 antibody TH-111 for detection of AML leukemic stem cells, and purging of autografts for stem cell transplantation.
33. Differences Between Gvhd and GVL May be Rather Quantitative and Not Dependent on a Malignant Transformation of the Target Cell
34. Targeting CD96 For Antibody Based Elimination Of Leukemic Stem Cells In AML: A New Strategy In Stem Cell Transplantation
35. Successful Mobilization, Intra-Apheresis Recruitment, and Harvest of Hematopoietic Progenitor Cells by Addition of Plerixafor and Subsequent Large-Volume Leukapheresis
36. Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96
37. PBSCT Similar to BMT Allows Active B-Lymphopoiesis Unless Severe GVHD Occurs.
38. Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini- Antibodies Directed against the AML Stem Cell Antigen CD96.
39. Immune Reconstitution after Allogeneic Stem Cell Transplantation - a Systematic Single Center Survey
40. Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.